The following is true of propafenone except: A. It is a weak Na+ channel blocker B. It markedly delays recovery of myocardial Na+ channels C. It has additional β-adrenergic blocking property D. It slows anterograde as well as retrograde conduction in the WPW bypass tract

The following is true of propafenone except:
A. It is a weak Na+ channel blocker
B. It markedly delays recovery of myocardial
Na+ channels
C. It has additional β-adrenergic blocking
property
D. It slows anterograde as well as retrograde
conduction in the WPW bypass tract
by

1 Answer

Answer :

A. It is a weak Na+ channel blocker
by

Related questions

The following is not true of quinidine: A. It blocks myocardial Na+ channels primarily in the open state B. It has no effect on myocardial K+ channels C. It produces frequency dependent blockade of myocardial Na+ channels D. It delays recovery of myocardial Na+ channels

Description : The following is not true of quinidine: A. It blocks myocardial Na+ channels primarily in the open state B. It has no effect on myocardial K+ channels C. It produces frequency dependent blockade of myocardial Na+ channels D. It delays recovery of myocardial Na+ channels

Last Answer : B. It has no effect on myocardial K+ channels

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

yocardial Na+ channel blockade by lignocaine has the following characteristic: A. It blocks inactivated Na+ channels more than activated channels B. It blocks activated Na+ channels more than inactivated channels C. It delays rate of recovery of Na+ channels D. It produces more prominent blockade of atrial than ventricular Na+ channels

Description : yocardial Na+ channel blockade by lignocaine has the following characteristic: A. It blocks inactivated Na+ channels more than activated channels B. It blocks activated Na+ channels more than inactivated ... Na+ channels D. It produces more prominent blockade of atrial than ventricular Na+ channels

Last Answer : A. It blocks inactivated Na+ channels more than activated channels

Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Description : Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : A. Carvedilol

Select the β -adrenergic blocker that has additional α 1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Description : Select the β -adrenergic blocker that has additional α 1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : A. Carvedilol

Choose the correct statement(s) about dofetilide: A. It is a pure class III antiarrhythmic B. It has no adrenergic/cholinergic receptor blocking property C. It selectively depresses the rapid component of delayed rectifier K+ current in myocardial fibres D. All of the above

Description : Choose the correct statement(s) about dofetilide: A. It is a pure class III antiarrhythmic B. It has no adrenergic/cholinergic receptor blocking property C. It selectively depresses the rapid component of delayed rectifier K+ current in myocardial fibres D. All of the above

Last Answer : D. All of the above

Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Description : Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Last Answer : A. It has additional α1 blocking property

Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Description : Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Last Answer : A. It has additional α1 blocking property

The following is true of β-adrenergic blocker therapy in CHF: A. They are added to conventional therapy after cardiac compensation is restored B. They are indicated only in severe (NYHA class IV) heart failure C. They are to be used only at low doses D. All of the above

Description : The following is true of β-adrenergic blocker therapy in CHF: A. They are added to conventional therapy after cardiac compensation is restored B. They are indicated only in severe (NYHA class IV) heart failure C. They are to be used only at low doses D. All of the above

Last Answer : A. They are added to conventional therapy after cardiac compensation is restored

Ergotamine relieves migraine by: A. Blocking vascular α adrenergic receptors B. Blocking vascular 5-HT2 receptors C. Dilating cranial arterio-venous shunt channels D. Constricting cranial vessels and reducing perivascular neurogenic inflammation

Description : Ergotamine relieves migraine by: A. Blocking vascular α adrenergic receptors B. Blocking vascular 5-HT2 receptors C. Dilating cranial arterio-venous shunt channels D. Constricting cranial vessels and reducing perivascular neurogenic inflammation

Last Answer : D. Constricting cranial vessels and reducing perivascular neurogenic inflammation

Labetalol has: A. More potent β adrenergic blocking than α blocking activity B. More potent α adrenergic blocking than β blocking activity C. Equal α and β adrenergic blocking activity D. β1 agonistic activity in addition to α and β adrenergic blockade

Description : Labetalol has: A. More potent β adrenergic blocking than α blocking activity B. More potent α adrenergic blocking than β blocking activity C. Equal α and β adrenergic blocking activity D. β1 agonistic activity in addition to α and β adrenergic blockade

Last Answer : A. More potent β adrenergic blocking than α blocking activity

Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve

Description : Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve

Last Answer : C. Do not block any effect of injected adrenaline

Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve stimulation

Description : Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve stimulation

Last Answer : C. Do not block any effect of injected adrenaline

Local anaesthetics block nerve conduction by: A. Blocking all cation channels in the neuronal membrane B. Hyperpolarizing the neuronal membrane C. Interfering with depolarization of the neuronal membrane D. Both ‘B’ and ‘C’ are correct

Description : Local anaesthetics block nerve conduction by: A. Blocking all cation channels in the neuronal membrane B. Hyperpolarizing the neuronal membrane C. Interfering with depolarization of the neuronal membrane D. Both ‘B’ and ‘C’ are correct

Last Answer : C. Interfering with depolarization of the neuronal membrane

The following antipsychotic drug has weak dopamine D2 but additional 5-HT2 blocking activity and benefits both positive and negative symptoms of schizophrenia: A. Loxapine B. Clozapine C. Pimozide D. Penfluridol

Description : The following antipsychotic drug has weak dopamine D2 but additional 5-HT2 blocking activity and benefits both positive and negative symptoms of schizophrenia: A. Loxapine B. Clozapine C. Pimozide D. Penfluridol

Last Answer : B. Clozapin

Compared to other antipsychotic drugs, the distinctive feature of penfluridol is: A. Very long duration of action B. Weak dopamine D2 blocking activity C. Lack of extrapyramidal side effects D. Additional 5-HT2 receptor blocking activity

Description : Compared to other antipsychotic drugs, the distinctive feature of penfluridol is: A. Very long duration of action B. Weak dopamine D2 blocking activity C. Lack of extrapyramidal side effects D. Additional 5-HT2 receptor blocking activity

Last Answer : A. Very long duration of action

The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

The β adrenergic blocker having β 1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β 1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

Amiloride inhibits K+ excretion in the distal tubules and collecting ducts by blocking: A. Electrogenic K+ channels B. Electrogenic Na+ channels C. Nonelectrogenic Na+-Cl– symport D. H+K+ATPase

Description : Amiloride inhibits K+ excretion in the distal tubules and collecting ducts by blocking: A. Electrogenic K+ channels B. Electrogenic Na+ channels C. Nonelectrogenic Na+-Cl– symport D. H+K+ATPase

Last Answer : B. Electrogenic Na+ channels

e primary mechanism by which general anaesthetics produce their action is: A. Affecting receptor operated ion channels in cerebral neurones B. Blocking voltage sensitive Na+ channels in neuronal membrane C. Depressing metabolic activity of cerebral neurones D. Blocking production of high energy phosphates in the brain

Description : e primary mechanism by which general anaesthetics produce their action is: A. Affecting receptor operated ion channels in cerebral neurones B. Blocking voltage sensitive Na+ channels in neuronal ... activity of cerebral neurones D. Blocking production of high energy phosphates in the brain

Last Answer : A. Affecting receptor operated ion channels in cerebral neurones

Which of the following drugs depresses automaticity of SA node as well as ectopic foci, abbreviates action potential duration of Purkinje fibres, and slows atrioventricular conduction: A. Propranolol B. Lignocaine C. Procainamide D. Bretylium

Description : Which of the following drugs depresses automaticity of SA node as well as ectopic foci, abbreviates action potential duration of Purkinje fibres, and slows atrioventricular conduction: A. Propranolol B. Lignocaine C. Procainamide D. Bretylium

Last Answer : A. Propranolol

Choose the correct statement about long acting calcium channel blocking drugs as antihypertensives: A. They are the most effective drugs in suppressing hypertensive left ventricular hypertrophy B. They are as effective as diuretics or β blockers in reducing cardiovascular/total mortality C. They compromise quality of life more than β blockers D. They have no beneficial effect in hypertensive/diabetic nephropath

Description : Choose the correct statement about long acting calcium channel blocking drugs as antihypertensives: A. They are the most effective drugs in suppressing hypertensive left ventricular hypertrophy B. They ... more than β blockers D. They have no beneficial effect in hypertensive/diabetic nephropath

Last Answer : B. They are as effective as diuretics or β blockers in reducing cardiovascular/total mortality

Adverse consequences of excess mineralocorticoid action include the following except: A. Na+ and water retention B. Acidosis C. Aggravation of CHF associated myocardial fibrosis D. Rise in blood pressure

Description : Adverse consequences of excess mineralocorticoid action include the following except: A. Na+ and water retention B. Acidosis C. Aggravation of CHF associated myocardial fibrosis D. Rise in blood pressure

Last Answer : B. Acidosis

Olanzapine has the following features except: A. It is an antipsychotic drug with weak D2 receptor blocking action B. It has potent 5-HT2 blocking and antimuscarinic actions C. It lowers seizure threshold D. It produces prominent extrapyramidal side effects

Description : Olanzapine has the following features except: A. It is an antipsychotic drug with weak D2 receptor blocking action B. It has potent 5-HT2 blocking and antimuscarinic actions C. It lowers seizure threshold D. It produces prominent extrapyramidal side effects

Last Answer : D. It produces prominent extrapyramidal side effect

The following is an orally active lignocaine congener used for both acute as well as chronic ventricular arrhythmias: A. Mexiletine B. Flecainide C. Moricizine D. Propafenone

Description : The following is an orally active lignocaine congener used for both acute as well as chronic ventricular arrhythmias: A. Mexiletine B. Flecainide C. Moricizine D. Propafenone

Last Answer : A. Mexiletine

Insulin release from pancreatic β cells is augmented by the following except: A. Ketone bodies B. Glucagon C. Vagal stimulation D. Alfa adrenergic agonists

Description : Insulin release from pancreatic β cells is augmented by the following except: A. Ketone bodies B. Glucagon C. Vagal stimulation D. Alfa adrenergic agonists

Last Answer : D. Alfa adrenergic agonist

Adrenergic β 1 selective blockers offer the following advantages except: A. Lower propensity to cause bronchospasm B. Less prone to produce cold hands and feet as side effect C. Withdrawal is less likely to exacerbate angina pectoris D. Less liable to impair exercise capacity

Description : Adrenergic β 1 selective blockers offer the following advantages except: A. Lower propensity to cause bronchospasm B. Less prone to produce cold hands and feet as side effect C. Withdrawal is less likely to exacerbate angina pectoris D. Less liable to impair exercise capacity

Last Answer : C. Withdrawal is less likely to exacerbate angina pectoris

The characteristic feature(s) of dihydropyridine calcium channel blockers is/are: A. They have minimal negative inotropic action on the heart B. They have no effect on A-V conduction C. They do not affect the activation-inactivation kinetics of the calcium channels D. All of the above

Description : The characteristic feature(s) of dihydropyridine calcium channel blockers is/are: A. They have minimal negative inotropic action on the heart B. They have no effect on A-V conduction C. They do not affect the activation-inactivation kinetics of the calcium channels D. All of the above

Last Answer : D. All of the above

In a patient of hypertension, the dose of propranolol that normalized blood pressure, reduced resting heart rate to 50/min. Which of the following β blockers will be most suitable for him as an alternative so that heart rate is not markedly reduced: A. Pindolol B. Celiprolol C. Bisoprolol D. Atenolol

Description : In a patient of hypertension, the dose of propranolol that normalized blood pressure, reduced resting heart rate to 50/min. Which of the following β blockers will be most suitable for him as an ... so that heart rate is not markedly reduced: A. Pindolol B. Celiprolol C. Bisoprolol D. Atenolol

Last Answer : A. Pindolol

In a patient of hypertension, the dose of propranolol that normalized blood pressure, reduced resting heart rate to 50/min. Which of the following β blockers will be most suitable for him as an alternative so that heart rate is not markedly reduced: A. Pindolol B. Celiprolol C. Bisoprolol D. Atenolol

Description : In a patient of hypertension, the dose of propranolol that normalized blood pressure, reduced resting heart rate to 50/min. Which of the following β blockers will be most suitable for him as an ... so that heart rate is not markedly reduced: A. Pindolol B. Celiprolol C. Bisoprolol D. Atenolol

Last Answer : A. Pindolol

Choose the correct statement about trimetazidine: A. It is a novel calcium channel blocker B. It improves tissue perfusion by modifying rheological property of blood C. It is an antianginal drug which acts by nonhaemodynamic mechanisms D. Both 'A' and 'B' are correct

Description : Choose the correct statement about trimetazidine: A. It is a novel calcium channel blocker B. It improves tissue perfusion by modifying rheological property of blood C. It is an antianginal drug which acts by nonhaemodynamic mechanisms D. Both 'A' and 'B' are correct

Last Answer : C. It is an antianginal drug which acts by nonhaemodynamic mechanisms

The principal action common to all class I antiarrhythmic drugs is: A. Na+ channel blockade B. K+ channel opening C. Depression of impulse conduction D. Prolongation of effective refractory period

Description : The principal action common to all class I antiarrhythmic drugs is: A. Na+ channel blockade B. K+ channel opening C. Depression of impulse conduction D. Prolongation of effective refractory period

Last Answer : A. Na+ channel blockade

The following is a tetracyclic antidepressant that has additional dopamine blocking and neuroleptic properties, as well as greater propensity to cause seizures in overdose: A. Amoxapine B. Doxepin C. Dothiepin D. Trazodone

Description : The following is a tetracyclic antidepressant that has additional dopamine blocking and neuroleptic properties, as well as greater propensity to cause seizures in overdose: A. Amoxapine B. Doxepin C. Dothiepin D. Trazodone

Last Answer : A. Amoxapine

The most probable mechanism of anticonvulsant action of phenytoin is: A. Facilitation of GABAergic inhibitory transmission B. Hyperpolarization of neurones C. Interaction with Ca2+ channels to promote Ca2+ influx D. Prolongation of voltage sensitive neuronal Na+ channel inactivation

Description : The most probable mechanism of anticonvulsant action of phenytoin is: A. Facilitation of GABAergic inhibitory transmission B. Hyperpolarization of neurones C. Interaction with Ca2+ channels to promote Ca2+ influx D. Prolongation of voltage sensitive neuronal Na+ channel inactivation

Last Answer : D. Prolongation of voltage sensitive neuronal Na+ channel inactivation

At the muscle end-plate, d-tubocurarine reduces the: A. Number of Na+ channels B. Duration for which the Na+ channels remain open C. Ion conductance of the open Na+ channel D. Frequency of Na+ channel opening

Description : At the muscle end-plate, d-tubocurarine reduces the: A. Number of Na+ channels B. Duration for which the Na+ channels remain open C. Ion conductance of the open Na+ channel D. Frequency of Na+ channel opening

Last Answer : D. Frequency of Na+ channel opening

Prazosin is an effective antihypertensive while nonselective α adrenergic blockers are not because: A. It is the only orally active α blocker B. It improves plasma lipid profile C. It does not concurrently enhance noradrenaline release D. It improves urine flow in males with prostatic hypertrophy

Description : Prazosin is an effective antihypertensive while nonselective α adrenergic blockers are not because: A. It is the only orally active α blocker B. It improves plasma lipid profile C. It does not concurrently enhance noradrenaline release D. It improves urine flow in males with prostatic hypertrophy

Last Answer : C. It does not concurrently enhance noradrenaline release

Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Description : Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Last Answer : A. Adrenaline

Prazosin is an effective antihypertensive while nonselective α adrenergic blockers are not because: A. It is the only orally active α blocker B. It improves plasma lipid profile C. It does not concurrently enhance noradrenaline release D. It improves urine flow in males with prostatic hypertrophy

Description : Prazosin is an effective antihypertensive while nonselective α adrenergic blockers are not because: A. It is the only orally active α blocker B. It improves plasma lipid profile C. It does not concurrently enhance noradrenaline release D. It improves urine flow in males with prostatic hypertrophy

Last Answer : C. It does not concurrently enhance noradrenaline release

The drug which produces vasoconstriction despite being an α adrenergic blocker is: A. Phenoxybenzamine B. Ergotamine C. Dihydroergotoxine D. Tolazoline

Description : The drug which produces vasoconstriction despite being an α adrenergic blocker is: A. Phenoxybenzamine B. Ergotamine C. Dihydroergotoxine D. Tolazoline

Last Answer : B. Ergotamine

Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Description : Vasomotor reversal phenomenon after administration of an α adrenergic blocker is seen with: A. Adrenaline B. Noradrenaline C. Isoprenaline D. All of the above drugs

Last Answer : A. Adrenaline

Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Description : Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Last Answer : D. Atenolol

Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Description : Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Last Answer : D. Esmolol

Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Description : Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Last Answer : D. Atenolol

Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Description : Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Last Answer : D. Esmolol

In a patient of myocardial infarction, β adrenergic blockers are used with the following aim/aims: A. To reduce the incidence of reinfarction B. To prevent cardiac arrhythmias C. To limit size of the infarct D. All of the above

Description : In a patient of myocardial infarction, β adrenergic blockers are used with the following aim/aims: A. To reduce the incidence of reinfarction B. To prevent cardiac arrhythmias C. To limit size of the infarct D. All of the above

Last Answer : D. All of the above

Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are corre

Description : Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are corre

Last Answer : D. Both ‘B’ and ‘C’ are correct

Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are correct

Description : Procainamide differs from quinidine in the following respect(s): A. It does not cause paradoxical tachycardia B. It has no α adrenergic blocking activity C. It has little antivagal action D. Both ‘B’ and ‘C’ are correct

Last Answer : D. Both ‘B’ and ‘C’ are correct

The following drug claimed to have a therapeutic effect in senile dementia has α adrenergic blocking activity: A. Piracetam B. Pyritinol C. Codergocrine D. Methylphenidate

Description : The following drug claimed to have a therapeutic effect in senile dementia has α adrenergic blocking activity: A. Piracetam B. Pyritinol C. Codergocrine D. Methylphenidate

Last Answer : C. Codergocrine

Which of the following is a long acting neuroleptic having specific antidopaminergic action, but little adrenergic or cholinergic blocking activity: A. Triflupromazine B. Thioridazine C. Clozapine D. Pimozide

Description : Which of the following is a long acting neuroleptic having specific antidopaminergic action, but little adrenergic or cholinergic blocking activity: A. Triflupromazine B. Thioridazine C. Clozapine D. Pimozide

Last Answer : D. Pimozide